Trial · NCT03762850
Adverse events248
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 248
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Sparsentan | 53 | 202 | |
| other | COVID-19 | Infections and infestations | Irbesartan | 46 | 202 | |
| other | Upper respiratory tract infection | Infections and infestations | Sparsentan | 18 | 202 | |
| other | Upper respiratory tract infection | Infections and infestations | Irbesartan | 18 | 202 | |
| other | Nasopharyngitis | Infections and infestations | Sparsentan | 15 | 202 | |
| other | Nasopharyngitis | Infections and infestations | Irbesartan | 16 | 202 | |
| other | Urinary tract infection | Infections and infestations | Sparsentan | 7 | 202 | |
| other | Urinary tract infection | Infections and infestations | Irbesartan | 12 | 202 | |
| other | Hyperkalaemia | Metabolism and nutrition disorders | Sparsentan | 32 | 202 | |
| other | Hyperkalaemia | Metabolism and nutrition disorders | Irbesartan | 26 | 202 | |
| other | Gout | Metabolism and nutrition disorders | Sparsentan | 11 | 202 | |
| other | Gout | Metabolism and nutrition disorders | Irbesartan | 10 | 202 | |
| other | Hyperuricaemia | Metabolism and nutrition disorders | Sparsentan | 7 | 202 | |
| other | Hyperuricaemia | Metabolism and nutrition disorders | Irbesartan | 11 | 202 | |
| other | Muscle spasms | Musculoskeletal and connective tissue disorders | Sparsentan | 14 | 202 | |
| other | Muscle spasms | Musculoskeletal and connective tissue disorders | Irbesartan | 17 | 202 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Sparsentan | 12 | 202 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Irbesartan | 16 | 202 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Sparsentan | 14 | 202 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Irbesartan | 13 | 202 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03762850/events